Antibe Therapeutics Announces Key US Distribution Partnership for its Subsidiary, Citagenix

Citagenix to be Regenerative Medicine Supplier for Darby Dental, a Leading Dental Distributor in the United States

TORONTO, CANADA — (October 26, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its subsidiary, Citagenix Inc. (“Citagenix”), has been selected by Darby Dental Supply, LLC (“Darby Dental”) to be its supplier of premium bone grafting and tissue regeneration products. Darby Dental has been in operation for nearly 70 years and has established itself as one of the largest and most trusted dental distributors in the United States.

Liz Meyers, Vice President of Marketing & Purchasing for Darby Dental, commented, “Citagenix’s comprehensive suite of high-quality bone grafts and barrier membranes is a very complementary fit for Darby’s portfolio of dental supplies. We are impressed with the level of professionalism and expertise of the Citagenix team, and look forward to helping increase their presence in the United States.”

“Building our market share in the United States is the number one priority for Citagenix, and key to our global growth strategy,” remarked Dan Legault, Antibe’s CEO. “Our US sales team has been actively identifying and engaging the right distribution partners to drive expansion of our footprint. We are excited to announce this partnership with Darby Dental, a well-respected and leading distributor in the US marketplace.”

Darby Dental was established in 1948 and is the largest all-telesales national distributor of dental merchandise and equipment to office-based practitioners in the United States. Through strategic distribution points, Darby Dental fulfills over one million shipments per year from leading manufacturers of dental products and equipment. For more information please visit: www.darby.com

About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com

Antibe's subsidiary, Citagenix Inc. ("Citagenix"), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Contact Information
Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
Tel: +1 416-473-4095
dan.legault@antibethera.com

Please sign up to our mailing list to receive regular news updates via e-mail.